Marco Investment Management LLC Sells 961 Shares of Stryker Co. (NYSE:SYK)

Marco Investment Management LLC lowered its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 1.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,552 shares of the medical technology company's stock after selling 961 shares during the quarter. Stryker accounts for about 1.7% of Marco Investment Management LLC's portfolio, making the stock its 17th biggest position. Marco Investment Management LLC's holdings in Stryker were worth $19,641,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Chicago Capital LLC raised its position in Stryker by 3.1% in the 4th quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock valued at $70,228,000 after buying an additional 5,841 shares during the last quarter. Zhang Financial LLC raised its position in Stryker by 55.0% in the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock valued at $41,366,000 after buying an additional 40,784 shares during the last quarter. Appleton Partners Inc. MA raised its position in Stryker by 5.0% in the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock valued at $10,521,000 after buying an additional 1,400 shares during the last quarter. Metis Global Partners LLC grew its stake in Stryker by 10.2% in the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock valued at $6,064,000 after purchasing an additional 1,561 shares in the last quarter. Finally, US Bancorp DE grew its stake in Stryker by 0.5% in the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock valued at $65,829,000 after purchasing an additional 976 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Remove Ads

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Price Performance

NYSE SYK traded down $3.03 during midday trading on Friday, hitting $379.28. The company had a trading volume of 1,961,830 shares, compared to its average volume of 1,209,637. The company has a market capitalization of $144.73 billion, a PE ratio of 48.88, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a 50-day moving average price of $382.45 and a 200-day moving average price of $372.99. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company posted $3.46 EPS. As a group, analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Analyst Ratings Changes

A number of research analysts have weighed in on SYK shares. Truist Financial raised their price target on Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research note on Thursday, January 30th. Barclays raised their price target on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Stifel Nicolaus raised their price target on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Wells Fargo & Company raised their price target on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Finally, JPMorgan Chase & Co. raised their price target on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.